Insights from cyanobacterial genomic and transcriptomic analyses into adaptation strategies in terrestrial environments.

Phylogenomic analysis of Nostocsp. MG11, a terrestrial cyanobacterium, and some terrestrial and freshwater Nostoc strains showed that the terrestrial strains grouped together in a distinctive clade, which reveals the effect of habitat on shaping Nostoc genomes. Terrestrial strains showed larger genomes and had higher predicted CDS contents than freshwater strains. Comparative genomic analysis demonstrated that genome expansion in the terrestrial Nostoc is supported by an increase in copy number of the core genes and acquisition of shared genes. Transcriptomic profiling analysis under desiccation stress revealed that Nostoc sp. MG11 protected its cell by induction of catalase, proteases, sucrose synthase, trehalose biosynthesis and maltodextrin utilization genes and maintained its normal metabolism during this condition by up-regulation of genes related to phycobilisomes and light reactions of photosynthesis, CO2 fixation and protein metabolism. These results provide insights into the strategies related to survival and adaptation of Nostoc strains to terrestrial environments.

Comparative analysis of Chlorosarcinopsis eremi mitochondrial genome with some Chlamydomonadales algae.

Chlorosarcinopsis eremi is a member of Chlamydomonadales algae which is isolated from terrestrial environments. In this study, the mitochondrial genome of C. eremi isolated from desert region of Iran, was represented for the first time. Following sequencing, assembly and annotation, comparative analyses of C. eremi and other available Chlamydomonadales algae complete mitochondrial genomes were performed. The mitochondrial genome of C. eremi was circular, had a low number of genes coding in the same strand with a minor amount of repeated sequences; same as other non-Reinhardtinia species of Chlamydomonadales algae. GC content of C. eremi mitochondrial genome was in normal range when compared with non-Chlamydomonadales organisms, but among Chlamydomonadales algae, C. eremi had a low GC content mitochondrial genome. C. eremi had the highest percent of non-coding sequences in comparison with other available Chlamydomonadales mitochondrial genomes which was related to intergenic regions. Identity analysis of protein-coding sequences of Chlamydomonadales mitochondrial genomes showed more divergences and may be related to the high mutation rate of mitochondrial genome reported in microbial eukaryotes.

Efficacy of a multiple-indication antiviral herbal drug (Saliravira®) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study.

BACKGROUND: The scientific researches on COVID-19 pandemic topics are headed to an explosion of scientific literature. Despite these global efforts, the efficient treatment of patients is an in-progress challenge. Based on a meta-study of published shreds of evidence about compounds and their botanic sources in the last six decades, a novel multiple-indication herbal compound (Saliravira®) has been developed. Based on the antiviral, anti-inflammatory, and immune-enhancing properties of its ingredients, we hypothesized that Saliravira® has the potential to act as an antiviral agent, accelerate treatment, and reduce undesirable effects of COVID-19. METHODS: In this randomized, controlled, open-label clinical trial, COVID-19 outpatients were included by RT-PCR test or diagnosis of physicians according to the symptoms. Participants were randomly divided into intervention and control groups to receive Saliravira® package plus routine treatments of COVID-19 or routine treatments of COVID-19 alone, respectively. Saliravira® package includes tablets, nasal-sinuses spray, oral-pharynx spray, and inhaler drops. The treatment was for 10 days and followed up till 23 days after admission. RESULTS: On the 8th day, the "mean reduction rates" of viral load of the patients in the intervention group was 50% lower compared to the control group with a p-value < 0.05. The improvement of 10 out of 14 COVID-19 symptoms in the intervention group was significantly accelerated. The mean treatment duration of patients in the intervention group was 4.9 days less than the control group. In addition, no patients in the intervention group were hospitalized compared to 28% of the control group needed to be hospitalized.